LUX-Lung 3: A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation

Trial Profile

LUX-Lung 3: A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Afatinib (Primary) ; Cisplatin; Pemetrexed
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LUX-Lung-3
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 23 Mar 2018 Results (n=1312) assessing the value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer using data of patients those with either EGFR mutation exon 19 deletion or exon 21 L858R mutations from five phase III randomized trials EURTAC, IPASS, ENSURE, LUX-Lung 3, and LUX-Lung 6, published in the Journal of Thoracic Oncology.
    • 16 Jan 2018 According to a Boehringer Ingelheim media release, based on a pooled analysis of LUX-Lung 2, LUX-Lung 3 and LUX-Lung 6 studies the U.S. Food and Drug Administration has approved a supplemental New Drug Application for Gilotrif (afatinib) for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have non-resistant epidermal growth factor receptor mutations as detected by an FDA-approved test. The FDA granted Priority Review status to the application.
    • 24 Nov 2017 Results assessing patient-reported outcomes stratified by EGFR mutation type from two phase III studies (LUX-Lung 3 and LUX-Lung 6) published in The Patient - Patient-Centered Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top